 |
Roche, Biogen Idec to suspend Ocrelizumab treatment of patients in RA programme
Wednesday, March 10, 2010 14:00 IST Basel
Roche and Biogen Idec announced their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme.
Read complete story ... (You will need to login first to read this story.)
|
 |

|